Edwin Kania
CIK 1255927 · last filed 2026-05-22
Edwin Kania is a corporate insider who has filed 33 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for TMDX, was dated May 22, 2026. Across all open-market trades the lifetime net is −$236.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $26.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$26.14M
10
33
-$235.98M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TMDX | Director | 309,874 | $80.21 | $24.85M | $2.79M | 12 | 2026-05-22 |
| MRNA | 10%+ Owner | 23,847 | $53.86 | $1.28M | -$11.50M | 2 | 2020-01-14 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 586,595 | $0.88 | $516.9K | -$3.74M | 2 | 2017-05-16 |
| Carisma Therapeutics Inc. (EBIO) Delisted | 10%+ Owner | 1,090,757 | — | — | -$1.37M | 1 | 2016-09-16 |
| MCRB | 10%+ Owner | 0 | $4.82 | $0 | -$220.80M | 1 | 2016-05-27 |
| ACCELERON PHARMA INC (XLRN) Delisted | Director | 529,154 | $178.75 | $94.59M | -$2.07M | 6 | 2015-04-08 |
| BG Medicine, Inc. (BGMD) Delisted | 10%+ Owner | 92,278 | — | — | -$203.3K | 3 | 2014-12-11 |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 10%+ Owner | 563,482 | $8.37 | $4.72M | $0 | 1 | 2014-02-19 |
| DNIB UNWIND, INC. (BIND) Delisted | 10%+ Owner | 1,542,616 | — | — | $900.0K | 1 | 2013-09-27 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 1,375,290 | $104.91 | $144.28M | $0 | 4 | 2009-07-21 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-22 | TMDX | Grant (A) | +2,922 | $0 | EDGAR |
| 2025-05-23 | TMDX | Grant (A) | +2,134 | $0 | EDGAR |
| 2024-05-28 | TMDX | Grant (A) | +732 | $0 | EDGAR |
| 2023-05-30 | TMDX | Grant (A) | +1,193 | $0 | EDGAR |
| 2023-03-02 | TMDX | Other (J) | +242,477 | $19.34M | EDGAR |
| 2022-06-06 | TMDX | Grant (A) | — | $0 | EDGAR |
| 2021-11-30 | TMDX | Buy (P) | +100,000 | $2.26M | EDGAR |
| 2021-11-22 | TMDX | Mixed | −816,854 | $0 | EDGAR |
| 2021-06-01 | TMDX | Grant (A) | — | $0 | EDGAR |
| 2020-01-14 | MRNA | Sell (S) | −475,000 | -$9.62M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.